Efficacy and Safety of the Combined Oral Contraceptive Ethinylestradiol/Drospirenone (Yasmin®) in Healthy Chinese Women A Randomized, Open-Label, Controlled, Multicentre Trial

被引:0
作者
Fan Guang-Sheng [1 ]
Bian Mei-Lu [2 ]
Cheng Li-Nan [3 ,4 ]
Cao Xiao-Ming [5 ]
Huang Zi-Rong [6 ]
Han Zi-Yan
Jing Xiao-Ping [7 ]
Li Jian [8 ]
Wu Shu-Ying [9 ]
Xiong Cheng-Liang [10 ]
Xiong Zheng-Ai [11 ]
Yue Tian-Fu [12 ]
机构
[1] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
[2] Peking China Japan Friendship Hosp, Beijing, Peoples R China
[3] Int Peace Matern & Child Hlth Hosp, China Welf Inst, Shanghai, Peoples R China
[4] Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China
[5] Tianjin Womens & Childrens Hlth Ctr, Tianjin, Peoples R China
[6] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China
[7] Peking Chao Yang Hosp, Beijing, Peoples R China
[8] Peking Obstet Gynecol Hosp, Beijing, Peoples R China
[9] Peking Univ, Hosp 3, Beijing 100871, Peoples R China
[10] Tongji Med Univ, Family Planning Res Inst, Shanghai, Peoples R China
[11] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China
[12] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
关键词
PREMENSTRUAL-SYNDROME; DROSPIRENONE; PROGESTOGEN; COMBINATION; ESTROGENS;
D O I
10.1007/BF03256908
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To evaluate and compare the contraceptive efficacy, bleeding pattern, side effects and other positive effects of a combined oral contraceptive (COC) containing drospirenone (DRSP) [Yasmin (R)] with those of a COC containing desogestrel (DSG) in healthy Chinese women. Methods: This was a randomized, open-label, controlled, multicentre study of 768 healthy Chinese women requiring contraception. The subjects were randomized to ethinylestradiol (EE) 30 mu g/DRSP 3 mg (n = 573) or EE 30 mu g/DSG 150 mu g (n = 195), at a ratio of 3 : 1. Each individual was treated for 13 cycles. Further visits were required at cycle 4, cycle 7, cycle 10 and cycle 13 of treatment. Weight, height and body mass index were evaluated at each visit. The Menstrual Distress Questionnaire (MDQ) was administered at baseline, visit 3 (cycle 7) and visit 5 (after cycle 13). Results: Baseline characteristics were similar between the two groups (p > 0.05). The Pearl Index (method failure) for EE/DRSP was 0.208 per 100 women-years, which was lower than that for EE/DSG (0.601 per 100 women-years). There were no significant differences between the treatment groups with regard to bleeding patterns. According to the MDQ subscale, improvements in water retention and increases in appetite during the intermenstrual period and in water retention and general well-being during the menstrual period in the EE/DRSP group (-0.297, -0.057, 0.033 and 0.150, respectively) were significantly improved compared with the EE/DSG group (-0.108, 0.023, 0.231 and -0.023, respectively) [all p < 0.05]. Other values that improved in both groups, particularly improvement in breast pain and tenderness and skin condition, were more evident in the EE/DRSP group (18.0%, 89/494; 12.6%, 62/494) than in the EE/DSG group (11.3%, 19/168; 5.4%, 9/168). Mean weight increased in the EE/DSG group (0.57 kg) while there was a significant decrease in mean weight (-0.28 kg) in the EE/DRSP group (p<0.01). Conclusions: Both EE/DRSP and EE/DSG have good contraceptive efficacy and a comparable bleeding pattern. EE/DRSP had a more favourable effect on weight and premenstrual symptoms than EE/DSG.
引用
收藏
页码:387 / 396
页数:10
相关论文
共 16 条
[1]   Effect of a combination of ethinylestradiol 30 μg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception [J].
Borges, Lavinia E. ;
Andrade, Rosires P. ;
Aldrighi, Jose M. ;
Guazelli, Cristina ;
Yazlle, Marta Edna H. D. ;
Isaia, Carlos F. ;
Petracco, Alvaro ;
Peixoto, Fabio C. ;
Camargos, Aroldo F. .
CONTRACEPTION, 2006, 74 (06) :446-450
[2]  
Brown C, 2002, J REPROD MED, V47, P14
[3]   Successful use of oral contraceptives [J].
Burke, AE ;
Blumenthal, PD .
SEMINARS IN REPRODUCTIVE MEDICINE, 2001, 19 (04) :313-321
[4]   Premenstrual syndrome, premenstrual dysphoric disorder, and premenstrual exacerbation of another disorder [J].
Dell, DL .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2004, 47 (03) :568-575
[5]   Conception and pharmacodynamic profile of drospirenone [J].
Elger, W ;
Beier, S ;
Pollow, K ;
Garfield, R ;
Shi, SQ ;
Hillisch, A .
STEROIDS, 2003, 68 (10-13) :891-905
[6]   SERUM LEVELS OF ANDROGENS ARE HIGHER IN WOMEN WITH PREMENSTRUAL IRRITABILITY AND DYSPHORIA THAN IN CONTROLS [J].
ERIKSSON, E ;
SUNDBLAD, C ;
LISJO, P ;
MODIGH, K ;
ANDERSCH, B .
PSYCHONEUROENDOCRINOLOGY, 1992, 17 (2-3) :195-204
[7]   DROSPIRENONE - A NOVEL PROGESTOGEN WITH ANTIMINERALOCORTICOID AND ANTIANDROGENIC ACTIVITY [J].
MUHN, P ;
FUHRMANN, U ;
FRITZEMEIER, KH ;
KRATTENMACHER, R ;
SCHILLINGER, E .
STEROID RECEPTORS AND ANTIHORMONES, 1995, 761 :311-335
[8]  
OBRIEN PMS, 1985, J REPROD MED, V30, P113
[9]   Drospirenone, a progestogen with antimineralocorticoid properties: a short review [J].
Oelkers, W .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 217 (1-2) :255-261
[10]  
Oelkers W, 2002, EUR J CONTRACEP REPR, V7, P19